You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
The partners aim to refine a saliva-based SARS-CoV-2 test developed by Yale that received Emergency Use Authorization from the FDA earlier this year.
In a non-exclusive deal, GlaxoSmithKline will use Adaptive Biotechnology's NGS-based ClonoSeq test to assess MRD across its hematology portfolio.
Genosity will combine its Integrated Genomic Toolkit with Israel-based Igentify's genetic counseling software, which both firms will comarket.
The test is designed to measure the expression of IFI27, a gene strongly correlated with disease progression in influenza and COVID-19.
The firm will partner with startup GeneproDx on thyroid cancer diagnostic development, while a separate agreement with Endpoint Health will entail CDx development for critical illness.
The deal with GeneproDx will focus on thyroid cancer, while the agreement with Endpoint Health will focus on CDx development for critical illnesses.
Inivata's Radar assay will be used to monitor circulating tumor DNA from multiple tumor types in trial participants following treatment with Maverick's MVC-101 candidate.
The firm is engaged in multiple clinical validation trials and aims to raise more than $100 million to launch its Helio Liver Test in the US early next year.
The deal provides clinicians with digital access to Flagship Bio's TissueInsight via Inspirata's Dynamyx digital pathology product.
The firms will conduct PacBio whole-genome sequencing on epilepsy patients to generate variant profiles that can help the development of diagnostic assays.